skip to content

Clinical Trials

MainTitle

Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities

This study is currently recruiting participants. (see Contacts and Locations)

Verified March 2017 by Colleen Kelley, Emory University

Sponsor
Emory University

Collaborator
Centers for Disease Control and Prevention

Information provided by (Responsible Party)
Colleen Kelley, Emory University

ClinicalTrials.gov Identifier
NCT02985996

First received: December 5, 2016
Last updated: April 9, 2017
Last Verified: March 2017
History of Changes
Purpose

Purpose

The purpose of this study is to determine the ability of new anti-HIV agents to penetrate different body compartments in HIV negative men who have sex with men and transgender women. These new agents might be considered for pre-exposure prophylaxis regimens in the future. This study will include 90 healthy, HIV-negative men who have sex with men and transgender women who are not taking hormones aged 18-49 years. Participant must be willing to participate in 1 of the 3 study phases, be willing to take Truvada® (PrEP) or Genvoya®, and willing to undergo blood draws, urethral swabs, and rectal biopsy procedures.

Condition Intervention Phase
HIV Infections

Drug : Truvada
Drug : Genvoya
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities

Further study details as provided by Colleen Kelley, Emory University:

Primary Outcome Measures

  • Changes in Intracellular emtricitabine triphosphate (FTC-TP) for Persons on Genvoya Compared to Truvada [ Time Frame: Baseline, Visit 4 (Up to ten days post drug) ]
    Intracellular emtricitabine triphosphate (FTC-TP) will be measured and compared from blood specimen in both arms from baseline to visit 4.
  • Changes in Intracellular tenofovir diphosphate (TFV-DP) for Persons on Genvoya Compared to Truvada [ Time Frame: Baseline, Visit 4 (Up to ten days post drug) ]
    Intracellular tenofovir diphosphate (TFV-DP) will be measured and compared from blood specimen in both arms from baseline to visit 4.
Secondary Outcome Measures:
  • Change in plasma emtricitabine (FTC) Concentration [ Time Frame: Baseline, Visit 4 (Up to ten days post drug) ]
    Plasma emtricitabine (FTC) concentration will be measured from blood specimen.
  • Change in plasma tenofovir disoproxil fumarate (TDF) Concentration [ Time Frame: Baseline, Visit 4 (Up to ten days post drug) ]
    Plasma tenofovir disoproxil fumarate (TDF) concentration will be measured from blood specimen.
  • Change in plasma tenofovir alafenamide (TAF) Concentration [ Time Frame: Baseline, Visit 4 (Up to ten days post drug) ]
    Plasma tenofovir alafenamide (TAF) concentration will be measured from blood specimen.
  • Change in plasma elvitegravir (EVG) Concentration [ Time Frame: Baseline, Visit 4 (Up to ten days post drug) ]
    Plasma elvitegravir (EVG) concentration will be measured from blood specimen.
  • Change in Rectal emtricitabine (FTC) Concentration [ Time Frame: Baseline, Visit 4 (Up to ten days post drug) ]
    Emtricitabine (FTC) concentration will be measured from rectal secretion specimen.
  • Change in Rectal tenofovir disoproxil fumarate (TDF) Concentration [ Time Frame: Baseline, Visit 4 (Up to ten days post drug) ]
    Tenofovir disoproxil fumarate (TDF), concentration will be measured from rectal secretion specimen.
  • Change in Rectal tenofovir alafenamide (TAF) Concentration [ Time Frame: Baseline, Visit 4 (Up to ten days post drug) ]
    Tenofovir alafenamide (TAF) concentration will be measured from rectal secretion specimen.
  • Change in Rectal elvitegravir (EVG) Concentration [ Time Frame: Baseline, Visit 4 (Up to ten days post drug) ]
    Elvitegravir (EVG) concentration will be measured from rectal secretion specimen.
  • Change in Intracellular emtricitabine (FTC) Concentration in peripheral blood mononuclear cells (PBMCs) [ Time Frame: Baseline, Visit 4 (Up to ten days post drug) ]
    Intracellular emtricitabine (FTC) concentration will be measured from isolated PBMCs collected via blood draw.
  • Change in Intracellular tenofovir disoproxil fumarate (TDF) Concentration in peripheral blood mononuclear cells (PBMCs) [ Time Frame: Baseline, Visit 4 (Up to ten days post drug) ]
    Intracellular tenofovir disoproxil fumarate (TDF) concentration will be measured from isolated PBMCs collected via blood draw.
  • Change in Intracellular tenofovir alafenamide (TAF) Concentration in peripheral blood mononuclear cells (PBMCs) [ Time Frame: Baseline, Visit 4 (Up to ten days post drug) ]
    Intracellular tenofovir alafenamide (TAF) concentration will be measured from isolated PBMCs collected via blood draw.
  • Change in Intracellular elvitegravir (EVG) Concentration in peripheral blood mononuclear cells (PBMCs) [ Time Frame: Baseline, Visit 4 (Up to ten days post drug) ]
    Intracellular elvitegravir (EVG) concentration will be measured from isolated PBMCs collected via blood draw.
  • Change in Intracellular emtricitabine (FTC) Concentration in Rectal Tissue [ Time Frame: Baseline, Visit 4 (Up to ten days post drug) ]
    Tissue emtricitabine (FTC) concentration will be measured from rectal biopsies and isolated cells.
  • Change in Intracellular tenofovir disoproxil fumarate (TDF) Concentration in Rectal Tissue [ Time Frame: Baseline, Visit 4 (Up to ten days post drug) ]
    Tissue tenofovir disoproxil fumarate (TDF) concentration will be measured from rectal biopsies and isolated cells.
  • Change in tenofovir alafenamide (TAF) Concentration in Rectal Tissue [ Time Frame: Baseline, Visit 4 (Up to ten days post drug) ]
    Tissue tenofovir alafenamide (TAF) concentration will be measured from rectal biopsies and isolated cells.
  • Change in elvitegravir (EVG) Concentration in Rectal Tissue [ Time Frame: Baseline, Visit 4 (Up to ten days post drug) ]
    Tissue elvitegravir (EVG) concentration will be measured from rectal biopsies and isolated cells.
  • Change in emtricitabine (FTC) Concentration in Penile Secretions [ Time Frame: Baseline, Visit 4 (Up to ten days post drug) ]
    Emtricitabine (FTC) concentrations will be measured from urethral and penile specimen.
  • Change in tenofovir disoproxil fumarate (TDF) Concentration in Penile Secretions [ Time Frame: Baseline, Visit 4 (Up to ten days post drug) ]
    Tenofovir disoproxil fumarate (TDF) concentrations will be measured from urethral and penile specimen.
  • Change in tenofovir alafenamide (TAF) Concentration in Penile Secretions [ Time Frame: Baseline, Visit 4 (Up to ten days post drug) ]
    Tenofovir alafenamide (TAF) concentrations will be measured from urethral and penile specimen.
  • Change in elvitegravir (EVG) Concentration in Penile Secretions [ Time Frame: Baseline, Visit 4 (Up to ten days post drug) ]
    Elvitegravir (EVG) concentrations will be measured from urethral and penile specimen.
  • PrEP Efficacy as measured by Inhibition of in vitro infection of rectal biopsies to HIV [ Time Frame: Duration of Study (Up to 3 years) ]
    Rectal biopsies will be subjected to in vitro infection with HIV to test for changes in susceptibility to virus infection.

Estimated Enrollment: 90
Study Start Date: February 6, 2017
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
No Intervention: Phase I/Pre-Drug
Ten participants will be asked to complete study phase 1. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
Experimental: Phase II/Short Course
Forty participants will be asked to complete study phase 2. Participants will be randomized to receive one dose of Truvada or Genvoya. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
Drug: Truvada

Truvada is intended for the treatment of HIV-1 infection. Truvada is a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in one tablet.

Drug: Genvoya

Genvoya is a 1-pill, once-a-day prescription medicine used to treat HIV-1. Genvoya is a combination of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamid in one tablet.

Experimental: Phase III/Steady State
Forty participants will be asked to complete study phase 3. Participants will be randomized to receive Truvada or Genvoya to be taken once daily for ten days. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
Drug: Truvada

Truvada is intended for the treatment of HIV-1 infection. Truvada is a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in one tablet.

Drug: Genvoya

Genvoya is a 1-pill, once-a-day prescription medicine used to treat HIV-1. Genvoya is a combination of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamid in one tablet.

Detailed Description:

Men who have sex with men (MSM) and Transgender women (TGW) who have sex with men continue to be disproportionately affected by HIV. Over 60% of new HIV infections in the US occur among MSM. The majority of HIV infections among MSM and TGW occur through exposure to the rectal mucosa during receptive anal intercourse (RAI). Pre-exposure prophylaxis (PrEP) is a new HIV prevention method that is recommended by CDC and WHO for MSM at risk of HIV infection. PrEP entails taking an anti-HIV medication (Truvada®; tenofovir/emtricitabine) on a daily basis to prevent HIV infection. However, current tenofovir- based regimens have shown to have side effects that researchers are hoping to reduce in newly developed anti-HIV agents. This study is designed to examine the ability of these new agents to penetrate mucosal tissues and potentially prevent HIV infection during RAI exposure for MSM and TGW.

Eligibility

Eligibility

Ages Eligible for Study: 18 Years to 49 Years  
Sexes Eligible for Study: Male  
Accepts Healthy Volunteers: No  

Criteria

Inclusion Criteria:

  • HIV-negative man who reports receptive anal sex with another man in the last 6 months
  • Male to female transgender women who have sex with men who report receptive anal intercourse with another man in the last 6 months and are not currently taking hormonal therapy or plan to take hormonal therapy for the duration of the study
  • Not currently taking PrEP and no plans to initiate during study
  • Able to provide informed consent in English
  • No plans for relocation in the next 3 months
  • Willing to undergo peripheral blood and rectal biopsy sampling
  • Willing to use study products as directed
  • Willing to abstain from receptive anal intercourse 3 days prior to starting study product and for the duration of the study and for 7 days after any rectal biopsy procedure.


Exclusion Criteria:
  • History of inflammatory bowel disease or other inflammatory, infiltrative, infectious or vascular condition involving the lower gastrointestinal tract that, in the judgment of the investigators, may be worsened by study procedures or may significantly distort the anatomy of the distal large bowel
  • Significant laboratory abnormalities at baseline visit, including but not limited to:
    1. Hgb ≤ 10 g/dL
    2. PTT > 1.5x ULN or INR > 1.5x ULN
    3. Platelet count <100,000
    4. Creatinine clearance <60
  • Any known medical condition that, in the judgment of the investigators, increases the risk of local or systemic complications of endoscopic procedures or pelvic examination, including but not limited to:
    1. Uncontrolled or severe cardiac arrhythmia
    2. Recent major abdominal, cardiothoracic, or neurological surgery
    3. History of uncontrolled bleeding diathesis
    4. History of colonic, rectal, or vaginal perforation, fistula, or malignancy
    5. History or evidence on clinical examination of ulcerative, suppurative, or proliferative lesions of the anorectal or vaginal mucosa, or untreated sexually transmitted disease with mucosal involvement
  • Continued need for, or use during the 14 days prior to enrollment, of the following medications:
    1. Aspirin or more than 4 doses of NSAIDs
    2. Warfarin, heparin (low-molecular weight or unfractionated), platelet aggregation inhibitors, or fibrinolytic agents
    3. Any form of rectally administered agent besides products lubricants or douching used for sexual intercourse
  • Continued need for, or use during the 90 days prior to enrollment, of the following medications:
    1. Systemic immunomodulatory agents
    2. Supraphysiologic doses of steroids
    3. Experimental medications, vaccines, or biologicals
  • Intent to use HIV antiretroviral pre-exposure prophylaxis (PrEP) during the study, outside of the study procedures
  • Symptoms of an untreated rectal sexually transmitted infection (e.g. rectal pain, discharge, bleeding, etc.)
  • Current use of hormonal therapy
  • Any other clinical condition or prior therapy that, in the opinion of the
investigator, would make the patient unsuitable for the study or unable to comply with the study requirements.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02985996

Contacts

Contact:   Colleen Kelley, MD, MPH 404-712-1823 colleen.kelley@emory.edu

Locations

United States, Georgia
Emory University Recruiting
Atlanta, Georgia, United States, 30322
Contact: Colleen Kelley, MD, MPH    404-712-1823    colleen.kelley@emory.edu

Sponsors and Collaborators

Emory University
Centers for Disease Control and Prevention

Investigators

Principal Investigator: Colleen Kelley, MD, MPH Emory University
More Information

More Information


Responsible Party: Colleen Kelley, Assistant Professor, Emory University  
ClinicalTrials.gov Identifier: NCT02985996   History of Changes  
Other Study ID Numbers: IRB00092488  
Study First Received: December 5, 2016  
Last Updated: April 9, 2017  

Studies a U.S. FDA-regulated Drug Product: No  
Studies a U.S. FDA-regulated Device Product: No  

Keywords provided by Colleen Kelley, Emory University:

Preventative Medicine
Infectious Diseases
Sexually Transmitted Diseases

Additional relevant MeSH terms:
HIV Infections
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination

ClinicalTrials.gov processed this data on October 17, 2017
This information is provided by ClinicalTrials.gov.